LORUS
THERAPEUTICS INC.
Material
Change Report
Section
75(2) of the Securities Act (Ontario)
Section
85(1)(b) of the Securities Act (British Columbia)
Section
146(1)(b) of the Securities Act (Alberta)
Section
84(1)(b) of The Securities Act, 1988 (Saskatchewan)
Section
81(2) of the Securities Act (Nova Scotia)
Section
76(2) of the Securities Act (Newfoundland)
1.
Reporting Issuer
Lorus
Therapeutics Inc.
2
Meridian Road
Toronto,
Ontario
M9W
4Z7
2.
Date of Material Change
December
6, 2005
3.
Press Release
The
press release prescribed by section 75(1) of the Securities Act
(Ontario) (and attached
hereto)
was issued at Toronto on December 6, 2005.
4.
Summary of Material Change
Lorus
Therapeutics Inc. (“Lorus”) announced that Elly Reisman has stepped down from
the Board of Directors
5.
Full Description of Material Change
Please
see attached press release.
6.
Reliance on Confidentiality Provisions of Securities
Legislation
Not
applicable.
7.
Omitted Information
No
significant facts remain confidential in, and no information has been omitted
from, this report.
8.
Senior Officers
For
further information please contact
Jim
A. Wright,
President
and C.E.O., at (416) 798-1200 (ext. 340).
9.
Statement of Senior Officer
The
foregoing accurately discloses the material change referred to
herein.
DATED
at Toronto, Ontario, this 9th day of
November
2005.
By:
“Jim A. Wright”
Jim
A. Wright
President
and C.E.O.
Lorus
Therapeutics. Inc.
Contacts:
|
Lorus
Therapeutics Inc.
|
Media
Contacts
|
US
Investor Relations
|
|
Grace
Tse
|
Susana
Hsu / Emily Brunner
|
Tim
Clemensen
|
|
Corporate
Communications
|
Mansfield
Communications
|
Rubenstein
& Co.
|
|
Tel:
(416) 798-1200 ext. 380
|
(416)
599-0024 / (212) 370-5045
|
(212)
843-9337
|
|
Email: ir@lorusthera.com
|
susana@mcipr.com
/ emily@mcipr.com
|
tim@rir1.com
|
LORUS
ANNOUNCES THAT ELLY REISMAN HAS STEPPED DOWN
FROM
THE BOARD OF DIRECTORS
TORONTO,
CANADA, December 6, 2005 - Lorus Therapeutics Inc. ('Lorus'), a
biopharmaceutical company specializing in the development and commercialization
of pharmaceutical products and technologies for the management of cancer,
today
announced that Mr. Elly Reisman has stepped down from the Board of Directors
to
pursue other business activities.
Mr.
Reisman indicated: “It is with regret that I hereby tender my resignation from
the Board of Directors of Lorus Therapeutics. I have enjoyed my time on the
Board and remain a strong supporter and shareholder of the
company.”
Mr.
Graham Strachan, Chairman of the Board, commented: “Mr. Reisman joined the Board
on November 29, 1999, and has been an active participant in Board deliberations
during his six year tenure. We thank him for his contributions and wish him
well
in his other business activities.”
About
Lorus
Lorus
is a
biopharmaceutical company focused on the development and commercialization
of
cancer therapies. Lorus' goal is to capitalize on its research, preclinical,
clinical and regulatory expertise by developing new drug candidates that
can be
used, either alone, or in combination, to successfully manage cancer. Through
its own discovery efforts and an acquisition and in-licensing program, Lorus
is
building a portfolio of promising anticancer drugs. Late-stage clinical
development and marketing may be done in cooperation with strategic
pharmaceutical partners. Lorus currently has products in human clinical trials
with a pipeline of eight clinical trials in Phase II clinical trial programs
and
recently has completed a Phase III registration clinical program. Lorus
Therapeutics Inc. is a public company listed on the Toronto Stock Exchange
under
the symbol LOR, and on the American Stock Exchange under the symbol LRP.
Virulizinâ
is a registered trademark of Lorus Therapeutics Inc.
Forward
Looking Statements
Except
for
historical information, this press release contains forward-looking statements,
which reflect the Company's current expectation and assumptions, and are
subject
to a number of risks and uncertainties that could cause actual results to
differ
materially from those anticipated. These forward-looking statements involve
risks and uncertainties, including, but not limited to, changing market
conditions, the Company's ability to obtain patent protection and protect
its
intellectual property rights, commercialization limitations imposed by
intellectual property rights owned or controlled by third parties, intellectual
property liability rights and liability claims asserted against the Company,
the
successful and timely completion of clinical studies, the establishment of
corporate alliances, the impact of competitive products and pricing, new
product
development, uncertainties related to the regulatory approval process, product
development delays, the Company's ability to attract and retain business
partners and key personnel, future levels of government funding, the Company's
ability to obtain the capital required for research, operations and marketing
and other risks detailed from time-to-time in the Company's ongoing quarterly
filings, annual information forms, annual reports and 40-F filings. We undertake
no obligation to publicly update or revise any forward-looking statements,
whether as a result of new information, future events or
otherwise. Lorus Therapeutics Inc.'s press releases are available
through the Company's Internet site: http://www.lorusthera.com/.